Erschienen in:
19.12.2017 | Progress in Hematology
New immunotherapy-based approach in allogeneic hematopoietic stem cell transplantation
verfasst von:
Yoshinobu Maeda
Erschienen in:
International Journal of Hematology
|
Ausgabe 2/2018
Einloggen, um Zugang zu erhalten
Excerpt
Allogeneic hematopoietic stem cell transplantation (HSCT) is a widely performed therapy for many hematologic malignancies. Recent progress with various sources of hematopoietic stem cells has enabled many more candidates to receive HSCT and a number of patients have now survived for years posttransplant. However, such patients still develop graft-versus-host disease (GVHD) and disease relapse are major causes of late death and morbidity. Now, several immunosuppressive agents are used for allogeneic transplantation recipients. However, therapeutic targets for GVHD, tumor and infection are overlapping and these immunosuppressive therapies are associated with increased relapse, impaired immune reconstitution, and more infections. In this review series, new immunotherapy-based approach in allogeneic HSCT, which are separating graft-versus-leukemia (GVL) effects and GVHD, are reviewed by experts. I believe this review series will deepen our understanding of transplantation immunology and recent progress in new immunotherapy-based therapy. …